Last reviewed · How we verify
Celecoxib 400 milligrams
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Celecoxib 400 milligrams |
|---|---|
| Sponsor | Pfizer |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
As a selective COX-2 inhibitor, celecoxib blocks the COX-2 enzyme preferentially over COX-1, which reduces inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract and kidneys. This selectivity was designed to provide anti-inflammatory and analgesic effects with a lower risk of gastrointestinal ulceration compared to non-selective NSAIDs.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Primary dysmenorrhea
- Ankylosing spondylitis
Common side effects
- Dyspepsia
- Abdominal pain
- Diarrhea
- Headache
- Hypertension
- Cardiovascular events (myocardial infarction, stroke)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celecoxib 400 milligrams CI brief — competitive landscape report
- Celecoxib 400 milligrams updates RSS · CI watch RSS
- Pfizer portfolio CI